- Home
- BCRX vs EWTX Comparison
BCRX vs EWTX Comparison
Compare BCRX & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- EWTX
- Stock Information
- Founded
- BCRX 1986
- EWTX 2017
- Country
- BCRX United States
- EWTX United States
- Employees
- BCRX N/A
- EWTX N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCRX Health Care
- EWTX Health Care
- Exchange
- BCRX Nasdaq
- EWTX Nasdaq
- Market Cap
- BCRX 1.8B
- EWTX 1.5B
- IPO Year
- BCRX 1994
- EWTX 2021
- Fundamental
- Price
- BCRX $8.27
- EWTX $15.57
- Analyst Decision
- BCRX Strong Buy
- EWTX Buy
- Analyst Count
- BCRX 10
- EWTX 9
- Target Price
- BCRX $16.70
- EWTX $39.89
- AVG Volume (30 Days)
- BCRX 2.3M
- EWTX 803.0K
- Earning Date
- BCRX 11-03-2025
- EWTX 11-06-2025
- Dividend Yield
- BCRX N/A
- EWTX N/A
- EPS Growth
- BCRX N/A
- EWTX N/A
- EPS
- BCRX N/A
- EWTX N/A
- Revenue
- BCRX $557,506,000.00
- EWTX N/A
- Revenue This Year
- BCRX $41.37
- EWTX N/A
- Revenue Next Year
- BCRX $7.56
- EWTX N/A
- P/E Ratio
- BCRX N/A
- EWTX N/A
- Revenue Growth
- BCRX 45.85
- EWTX N/A
- 52 Week Low
- BCRX $6.02
- EWTX $10.60
- 52 Week High
- BCRX $11.31
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- BCRX 43.55
- EWTX 64.68
- Support Level
- BCRX $8.02
- EWTX $13.93
- Resistance Level
- BCRX $8.68
- EWTX $15.12
- Average True Range (ATR)
- BCRX 0.22
- EWTX 0.71
- MACD
- BCRX 0.01
- EWTX 0.10
- Stochastic Oscillator
- BCRX 37.88
- EWTX 90.29
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.